Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-18
2005-01-18
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
57, C530S300000, C424S085100, C424S184100, C424S185100
Reexamination Certificate
active
06844314
ABSTRACT:
Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: WO 9941247 (1999-08-01), None
Plata-Salaman et al. Epidermal growth factor and the nervous system. Peptides 12(3): 653-663, 1991.*
George et al. Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J. Neurosci 15(10): 6445-6452, 1995.*
Petrovich et al. Pentoxifylline suppression of TNF-alpha mediated axonal degeneration in the rabbit optic nerve. Neurol Res. 19(5) : 551-554, 1997.*
Bradbury et al. NT-3, but not BDNF, prevents atrophy and death of axotomized spinal cord projection neurons. Eur J Neurosci 10(10) :3058-3068, 1998.*
Pan et al. Tumor necrosis factor-alpha: a neuromodulator in the CNS. Neurosci Biobehav Rev 21(5) : 603-613, 1997.*
Wang et al., Pathogenesis of axonal degeneration: parallels between wallerian degeneration and vincristine neuropathy. J Neuropath Exp Neurol 59(7): 599-606, 2000.*
Jackowski. Brit J Neurosurgery 9: 303-317, 1995.*
Teitelbaum et al. Immunomodulation of experimental autoimmune encephalomeylitis by oral administration of copolymer 1. Proc Natl Acad Sci USA 96:3842-3847, 1999.*
Schori et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implication for glaucoma. Proc Natl Acad Sci USA 98: 3398-3403, 2001.*
Kipnis et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97: 7446-7451, 2000.*
Schwartz, M. Drug Develop Res 50(3-4): 223-225, 2000.*
Arnon et al. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol. 243(4 Suppl 1):S8-13; 1996.*
Teitelbaum D et al. Copolymer 1: from basic research to clinical application. Cell Mol Life Sci. 53(1)24-28, 1997.*
Kipnis et al. Trends Molec Med 8(7): 319-323, 2002.*
Miller, A et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 92(1-2):113-121, 1998.*
Halliday et al. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 27: 1-8, 2000.*
Feigin et al. Recent advances in Huntington's diseas: implication for experimental therapeutics. Curr Opin Neurol 15: 483-489, 2002.*
Steece-Collier et al. Etiology of Parkinson's disease: genetics and environment revisited. Proc Natl Acad Sci USA 99(22): 13972-13974, 2002.*
Aharoni et al, “Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis”,Proc. Natl. Acad. Sci. USA94:10821-10826 (1997).
Aharoni et al “Cop-1 specific suppressor cells inhibit experimental allergic encephalomyelitis induced by either mouse spinal cord homogenate or proteolipid protein peptide 139-151”,Neurology, Meeting Info.: 49thAnn. Meeting of the American Academy of Neurology, vol. 48, No. 3 (suppl. 2), p. A422 XP 001029141 (1997) (abstract).
Teva; Yeda; Hoechst Marion Roussel, “Copolymer-1, Glatiramer Acetate, Copaxone®: Agent for Multiple Sclerosis”,Drugs of the Future, vol. 23, No. 2 (1998).
Edwards et al, “Peptides as drugs”,Q.J.M. Monthly Journal of the Association of Physicians, vol. 92, No. 1, pp. 1-4, XP 001029184 (1999).
Cohen Irun R.
Eisenbach-Schwartz Michal
Kipnis Jonathan
Sela Michael
Yoles Eti
Browdy and Neimark PLLC
Kemmerer Elizabeth
Yeda Research & Development Co. Ltd.
LandOfFree
Use of copolymer 1 and related peptides and polypeptides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of copolymer 1 and related peptides and polypeptides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of copolymer 1 and related peptides and polypeptides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3367034